Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1

Completed

Conditions: Squamous Cell Cancer
Head and Neck Cancer

Interventions: Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin

First Posted Date: 2009-11-19

Last Posted Date: 2019-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 48

Registration Number: NCT01016769

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States

and more 2 locations

Percutaneous Renal Tumor Cryoablation Followed by Biopsy

Phase 1

Completed

Conditions: Renal Cancer

Interventions: Procedure: percutaneous cryoablation

First Posted Date: 2009-11-13

Last Posted Date: 2016-01-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01012427

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Phase 2

Completed

Conditions: Brain Cancer

Interventions: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan

First Posted Date: 2009-11-13

Last Posted Date: 2022-03-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT01012609

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

and more 9 locations

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: lenalidomide

First Posted Date: 2009-11-11

Last Posted Date: 2017-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT01011894

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Active, not recruiting

Conditions: Melanoma

Interventions: Behavioral: screening questionnaire

First Posted Date: 2009-10-30

Last Posted Date: 2023-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 85

Registration Number: NCT01004952

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Acupuncture for the Treatment of Chronic Lymphedema

Phase 2

Completed

Conditions: Breast Cancer
Lymphedema

Interventions: Procedure: Acupuncture

First Posted Date: 2009-10-29

Last Posted Date: 2012-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT01003951

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information

Completed

Conditions: Colon Cancer
Rectal Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2009-10-29

Last Posted Date: 2014-12-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 177

Registration Number: NCT01003600

Locations: 🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Genomic Structural Variation in Cancer Susceptibility

Active, not recruiting

Conditions: Breast Cancer
Sarcoma
Colon Cancer
Germ Cell Cancer
Neuroblastoma
Rectal Cancer

First Posted Date: 2009-10-16

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1275

Registration Number: NCT00996710

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Pasireotide (SOM230)
Other: placebo

First Posted Date: 2009-10-14

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 439

Registration Number: NCT00994110

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: oral erlotinib and pulsed doses of oral AT-101

First Posted Date: 2009-10-02

Last Posted Date: 2015-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT00988169

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy